Literature DB >> 2689797

Medical uses of mylabris in ancient China and recent studies.

G S Wang1.   

Abstract

Mylabris is the dried body of the Chinese blister beetle. The species used in medicine are Mylabris phalerata and M. cichorii. The use of mylabris as a traditional medicine in China can be traced back more than 2000 years, and it is still used as a folk medicine today. In recent studies, it has been found that mylabris possesses antitumor properties, increases the number of leucocytes, and has irritant effects on the urinary organs. The active constituent of mylabris is cantharidin. The synthesis of cantharidin is rather difficult. In order to find a less toxic analogue of cantharidin, its hydrolytic compound, disodium cantharidate, and its demethylated form, norcantharidin, were prepared. By biochemical and biological methods, it was found that these compounds may affect cancer cells in several ways. In clinical studies, antihepatoma effectiveness sequentially increased from cantharidin to disodium cantharidate to norcantharidin. Disodium cantharidate showed less urinary irritation than cantharidin while norcantharidin showed little to no such irritation. It appears that the two methyl groups of cantharidin are not the main functional groups for antitumor activity and for the stimulation of bone marrow but are associated with urinary irritation. Hydrocantharidimide, methylcantharidimide and dehydronorcantharidin have also been studied. All these compounds, except the last one, have been produced as antitumor agents in China. Since demethylated cantharidin may be prepared by total synthesis, it may be more suitable for medical investigation than cantharidin itself.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2689797     DOI: 10.1016/0378-8741(89)90062-7

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  93 in total

1.  Apoptosis induced by norcantharidin in human tumor cells.

Authors:  Zhen-Xiao Sun; Qing-Wen Ma; Tian-De Zhao; Yu-Lin Wei; Guang-Sheng Wang; Jia-Shi Li
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture.

Authors:  Cheng Chang; Youqing Zhu; Xiaoyan Tang; Wenhui Tao
Journal:  Mol Biol Rep       Date:  2010-03-24       Impact factor: 2.316

Review 3.  Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.

Authors:  Ying Li; Yan Ge; Fu You Liu; You Ming Peng; Lin Sun; Jun Li; Qiong Chen; Yan Sun; Kun Ye
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

Review 4.  Targeting protein serine/threonine phosphatases for drug development.

Authors:  Jamie L McConnell; Brian E Wadzinski
Journal:  Mol Pharmacol       Date:  2009-03-19       Impact factor: 4.436

5.  Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells.

Authors:  Yan-Nian Chen; Chi-Chih Cheng; Jung-Chou Chen; Wei Tsauer; Shih-Lan Hsu
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

6.  Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial.

Authors:  Maurice A Recanati; Katherine J Kramer; John J Maggio; Conrad R Chao
Journal:  Clin Exp Obstet Gynecol       Date:  2018       Impact factor: 0.146

7.  Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors.

Authors:  Matthew S Kelker; Rebecca Page; Wolfgang Peti
Journal:  J Mol Biol       Date:  2008-11-01       Impact factor: 5.469

8.  8-Phenyl-10-oxa-8-aza-tricyclo-[4.3.0.1]decane-7,9-dione.

Authors:  Wen-Zhong Zhu; Qiu-Yue Lin
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-01-10

9.  Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells.

Authors:  Cheng Chang; You-Qing Zhu; Juan-Juan Mei; Shi-Quan Liu; Jun Luo
Journal:  J Exp Clin Cancer Res       Date:  2010-11-09

10.  (3aRS,4SR,7RS,7aSR)-2-(Tricyclo-[3.3.1.1]decan-1-yl)-4,5,6,7-tetra-hydro-4,7-epoxy-isoindoline-1,3-dione.

Authors:  Zaiyou Tan; Lin Luo; Erjia Zhu; Ruisi Yan; Zhuohui Lin
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.